<https://rdf.molmedb.upol.cz/reference/ref3639> <http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>;
	<http://purl.org/ontology/bibo/pmid> "29628327"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/doi> "10.1016/j.bmcl.2018.03.090"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM491335>,
		<https://rdf.molmedb.upol.cz/interaction/membrane21>;
	<http://purl.org/dc/terms/bibliographicCitation> "Islam I, Yuan S, Wei RG, Xu W, Morrissey M, Mohan R, Zheng D, DiMella A, Dunning L, Snider M, Subramanyam B, Tseng JL, Bryant JA, Buckman BO.: Reversible, orally available ADP receptor (P2Y<sub>12</sub>) antagonists Part I: Hit to lead process. Bioorg Med Chem Lett, Volume 28 (9), 2018"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1025456> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3639> .
